Abstract
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Dabigatran - A New Chapter in Anticoagulation
Volume: 10 Issue: 2
Author(s): Shameer Ahmed, Vadim Levin, Robert Malacoff and Matthew W. Martinez
Affiliation:
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Abstract: For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Export Options
About this article
Cite this article as:
Ahmed Shameer, Levin Vadim, Malacoff Robert and W. Martinez Matthew, Dabigatran - A New Chapter in Anticoagulation, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (2) . https://dx.doi.org/10.2174/187152512800388911
DOI https://dx.doi.org/10.2174/187152512800388911 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Fused Heterocyclic Flavonoids: Potent Candidates as Anti- Inflammatory and Anti-Allergic Agents in the Treatment of Asthma
Current Bioactive Compounds Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments
Current Pharmaceutical Design The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews The Socioeconomic Effects of Uncontrolled Hypertension
Current Vascular Pharmacology Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Cerebral Microinfarcts and Dementia: A Systematic Review and Metaanalysis
Current Alzheimer Research Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry ACKNOWLEDGEMENT
Recent Patents on Cardiovascular Drug Discovery Cell Death and Apoptosis in Ostearthritic Cartilage
Current Drug Targets QbD-Enabled Systematic Development of Ileo-Colonic Targeted Novel Mucoadhesive Microspheres of Flurbiprofen
Current Drug Delivery Mesoporous Bioactive Glass Scaffold Delivers Salvianolic Acid B to Promote Bone Regeneration in a Rat Cranial Defect Model
Current Drug Delivery Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design Meet Our Editorial Board Member
Cardiovascular & Hematological Disorders-Drug Targets Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews Management of Hemophilic Arthropathy of the Ankle
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections
Recent Patents on Biomarkers Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface
Current Medical Imaging